Stockwinners Market Radar for October 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:40 EDT Newmont reaches agreement to end strike at Minera Penasquito - Newmont confirms it has reached a preliminary agreement with the National Union of Mine, Metal, and Allied Workers of the Mexican Republic aiming to end the strike initiated by the Union on June 7 at Minera Penasquito in the Mexican state of Zacatecas. The preliminary agreement was ratified by the General Assembly of the Union on October 5. This preliminary agreement is intended to be formalized into a definitive agreement, which the parties will have to agree, approve, sign, and file with the Federal Labor Tribunal for Collective Affairs in Mexico City for final approval. This process is expected to conclude in the coming days, which would bring the strike to an end and enable the Company to start the execution of the return to work plan to ensure a safe restart of operations.

17:23 EDT General Motors says negotiations with UAW 'remain ongoing' - General Motors stated: "Negotiations remain ongoing, and we will continue to work toward finding solutions to address outstanding issues. Our goal remains to reach an agreement that rewards our employees and allows GM to be successful into the future." Reference Link

17:10 EDT US Foods awarded $145.31M Defense Logistics Agency contract - US Foods has been awarded a maximum $145.31M fixed-price with economic-price-adjustment, indefinite-quantity contract for full-line food distribution. This was a sole-source acquisition using justification 10 U.S. Code 2304 (c)(1), as stated in Federal Acquisition Regulation 6.302-1. This is one-year two-month contract with no option periods. The ordering period end date is December 7, 2024. Using customers are Air Force, Army, Marine Corps, and other federal civilian agencies. Type of appropriation is fiscal 2024 through 2025 defense working capital funds. The contracting agency is the Defense Logistics Agency Troop Support.

17:03 EDT Borqs Technologies announces 1-for-12 reverse split - Borqs Technologies announced that its board of directors has approved a 1-for-12 reverse split of the company's ordinary shares. The reverse stock split is anticipated to take effect on October 10. Accordingly, at the effective date, every twelve of the company's ordinary shares issued and outstanding will be automatically converted into one ordinary share of the company. The company's ordinary shares are expected to begin trading on Nasdaq Capital Market on a post-split basis beginning on the effective date, under a new CUSIP number: G1466B145.

16:55 EDT Shift Technologies trading halted, news pending

16:25 EDT Bombardier CEO 'applauds' Quebec motion over CMMA contract procurement process - Bombardier president and CEO Eric Martel said in a statement, "On behalf of Bombardier, our 17,000 employees and our coast-to-coast supply chain, I applaud the unanimous motion passed yesterday in the National Assembly of Quebec urging the federal government to follow an open procurement process in awarding the Canadian Multi-Mission Aircraft contract (CMMA). Further to the premiers of Ontario and Quebec joining forces last July to call on the federal government to launch a fair procurement process, this latest action from the National Assembly of Quebec clearly demonstrates the importance of the aerospace industry in our country. Bombardier's made-in-Canada solution is based on the proven and reliable Global 6500 business jet, which is supported by an extensive Canadian supply chain, including more than 40 suppliers from Quebec's rich aerospace ecosystem. Furthermore, allowing Bombardier and its partners to bid on the CMMA project will showcase Canada's expertise and defense innovation on the world stage. Bombardier's next-generation solution will ultimately bring better value, better performance and better long-term economic impact for Canadians. We look forward to proudly presenting our bid, and seek clarity on a timeframe for a tender as part of a fair and lawful government process."

16:06 EDT Anebulo Pharmaceuticals names Richie Cunningham CEO - Anebulo Pharmaceuticals announced that Richie Cunningham has been appointed as Anebulo's Chief Executive Officer, replacing Simon Allen. "Anebulo has positioned ANEB-001 for success and I look forward to working with the leadership team and board of directors to achieve Anebulo's strategic short- and long-term objectives. I am excited about the prospects of making a positive impact in the lives of patients and enhancing the value for all shareholders," said Cunningham. Most recently, Mr. Cunningham served as CEO at Tyme where he led the company through a merger with Syros Pharmaceuticals. Prior to Tyme, he was CEO at Icagen, leading the company through two transformational acquisitions. While CEO at Icagen, he oversaw the successful negotiation and execution of multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation. Prior to joining Icagen, Mr. Cunningham was an executive with Boehringer Ingelheim, where he held a variety of strategic and operational roles, including the launch of multiple products at Boehringer Ingelheim.

16:04 EDT Addex Therapeutics announces one for twenty reverse ADS split - Addex Therapeutics announced that it plans to change the ratio of its American Depositary Shares, or ADSs, to its ordinary shares from the current ADS Ratio of one ADS to six ordinary shares to a new ADS Ratio of one ADS to 120 ordinary shares. The company anticipates that the ADS ratio change will be effective on or about October 23. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one for 20 reverse ADS split and is intended to enable the company to regain compliance with the Nasdaq minimum bid price requirement.

15:18 EDT Jin Medical International Ltd trading resumes

15:06 EDT ALX Oncology trading resumes

15:04 EDT ALX Oncology jumps 35% to $8.83, halted for volatility

14:26 EDT UAW says on track to have all subcommittee issues addressed - In a live stream on Facebook Live, United Auto Workers president Shawn Fain said that the union is on track to have all subcommittee issues addressed, and is "winning," "making progress," and "moving in the right direction."

14:20 EDT UAW was ready to strike at GM's Arlington facility before EV battery agreement - In a live stream on Facebook Live, United Auto Workers president Shawn Fain said the union was ready to strike at GM's (GM) Arlington, Texas facility before the EV battery agreement was reached. Fain added that the union is making "significant progress" in deal talks with GM, Ford (F), and Stellantis (STLA).

13:55 EDT Snap issued preliminary enforcement notice in U.K. over AI chatbot - The U.K. Information Commissioner's Office has issued Snap, Inc and Snap Group Limited with a preliminary enforcement notice over potential failure to properly assess the privacy risks posed by Snap's generative AI chatbot 'My AI'. The preliminary notice sets out the steps which the Commissioner may require, subject to Snap's representations on the preliminary notice. If a final enforcement notice were to be adopted, Snap may be required to stop processing data in connection with 'My AI'. This means not offering the 'My AI' product to UK users pending Snap carrying out an adequate risk assessment. Snap launched the 'My AI' feature for UK Snapchat+ subscribers in February 2023, with a roll out to its wider Snapchat user base in the UK in April 2023. The chatbot feature, powered by OpenAI's GPT technology, marked the first example of generative AI embedded into a major messaging platform in the UK. As at May 2023 Snapchat had 21 million monthly active users in the UK. The ICO's investigation provisionally found the risk assessment Snap conducted before it launched 'My AI' did not adequately assess the data protection risks posed by the generative AI technology, particularly to children. The assessment of data protection risk is particularly important in this context which involves the use of innovative technology and the processing of personal data of 13 to 17 year old children. The Commissioner's findings in the notice are provisional. No conclusion should be drawn at this stage that there has, in fact, been any breach of data protection law or that an enforcement notice will ultimately be issued. The ICO will carefully consider any representations from Snap before taking a final decision. Reference Link

13:06 EDT Baker Hughes reports U.S. rig count down 4 to 619 rigs - Baker Hughes reports that the U.S. rig count is down 4 from last week to 619 with oil rigs down 5 to 497, gas rigs up 2 to 118 and miscellaneous rigs down 1 to 4. The U.S. Rig Count is down 143 rigs from last year's count of 762 with oil rigs down 105, gas rigs down 40 and miscellaneous up 2. The U.S. Offshore Rig Count is unchanged at 20, up 7 year-over-year. The Canada Rig Count is down 11 from last week to 180, with oil rigs down 7 to 108 gas rigs down 4 to 72. The Canada Rig Count is down 35 from last year's count of 215, with oil rigs down 40, and gas rigs up 5.

12:52 EDT Virgin Galactic reports 'Galactic 04' mission landed safely - Virgin Galactic tweeted: "Welcome back to Earth, #Galactic04! Our pilots, crew and spaceship have landed safely at Spaceport America, New Mexico." Reference Link

12:47 EDT EA says 'EA SPORTS FC 24' draws 11.3M players in first week - Electronic Arts shared shared details on fan engagement across its "EA SPORTS FC" ecosystem, with more than 11.3M players worldwide, including through EA Play, playing "EA SPORTS FC 24" through its first week. "EA SPORTS FC Mobile", broke EA SPORTS Mobile Football franchise records with 2.2M people installing the application on the first day. In the 10 days since launch, a total of more than 11.2M new users have downloaded the mobile game. "We're thrilled to have so many fans jumping into The World's Game in both EA SPORTS FC 24 and FC Mobile in just the first few days since launch," said Cam Weber, President of EA SPORTS. "In addition to welcoming back millions of our longtime players, new players in FC 24 are up nearly 20% year over year, showing the excitement of football fans everywhere to join the Club. We are building the world's biggest football community through EA SPORTS FC, and we're just getting started."

12:00 EDT Park Aerospace falls -8.6% - Park Aerospace is down -8.6%, or -$1.35 to $14.45.

12:00 EDT Clearway Energy rises 9.3% - Clearway Energy is up 9.3%, or $1.74 to $20.50.

12:00 EDT Nuscale Power rises 14.5% - Nuscale Power is up 14.5%, or 68c to $5.36.

10:56 EDT Maison Solutions Inc trading resumes

10:29 EDT Korea warns Google, Apple of potential fines over apps marketing - The Korea Communications Commission is going to impose corrective measures and penalty surcharges for Google (GOOGL) and Apple (AAPL) on October 6, according to the result of a fact-checking investigation over unfair practices, including forcing specific payment methods of app market operators initiated August 16, 2022. The KCC reasoned that Google and Apple violated prohibited acts of the Telecommunications Business Act as the two tech giants forced specific payment methods and unfairly delayed application assessment by abusing their market positions. The KCC said: "The enforcement of specific payment methods by Google and Apple is a significant concern because it has the potential to undermine the primary goal of the amended act in September 2021, which is to promote fair competition in the app market. In addition, the KCC notified a corrective measure draft for Apple's discriminatory charging of fees to domestic app developers. The KCC will make a final decision on up to 68 billion won penalty surcharge, including 47.5 billion won for Google and 20.5 billion won for Apple, after hearing opinions from business operators on the draft and going through processes, such as deliberation and decision." Reference Link

10:00 EDT AES Corp. falls -7.8% - AES Corp. is down -7.8%, or -98c to $11.62.

10:00 EDT Philips falls -9.0% - Philips is down -9.0%, or -$1.77 to $17.93.

10:00 EDT Pioneer Natural rises 9.4% - Pioneer Natural is up 9.4%, or $20.14 to $235.10.

09:57 EDT Anywhere Real Estate announces $83.5M class action litigation settlement - Anywhere Real Estate announced the terms of a settlement agreement the company has entered into to settle all claims asserted against Anywhere in the Burnett and Moehrl antitrust class action litigation. Under the terms of the proposed nationwide settlement, which is subject to both preliminary and final court approval, Anywhere has agreed to provide monetary relief of $83.5M, which it says is substantially in line with the company's financial planning as well as injunctive relief. The company does not expect the terms of the proposed settlement to have a material impact on its results of operations, liquidity, or cash flows. The proposed settlement resolves, on a nationwide basis, all claims asserted against Anywhere in the Burnett and Moehrl cases and releases the Company, all subsidiaries, brands, affiliated agents, and franchisees. The proposed settlement is not an admission of liability, nor does it concede or validate any of the claims asserted against Anywhere. "While the Company does not control the timeline, a hearing for preliminary approval of the settlement is expected to occur in November 2023 with final court approval expected in mid-2024," it added.

09:48 EDT Jaguar Global Growth Corporation I trading resumes

09:47 EDT Philips falls -9.5% - Philips is down -9.5%, or -$1.87 to $17.84.

09:47 EDT ProShares Ultra Silver rises 4.7% - ProShares Ultra Silver is up 4.7%, or $1.03 to $22.94.

09:47 EDT Nuscale Power rises 9.8% - Nuscale Power is up 9.8%, or 46c to $5.14.

09:41 EDT Athena Consumer Acquisition Corp trading halted, volatility trading pause

09:18 EDT WeightWatchers enhances WeightWatchers for Business offering - WeightWatchers announced that WeightWatchers for Business has fully integrated WW's science-proven behavioral program with its virtual obesity clinic and medication management. The Company now offers a full spectrum weight health platform designed for employers and health plans, that delivers individualized member pathways based on true clinical need. As prevalence of chronic diseases increases, organizations are challenged with higher costs, with experts predicting a 2-10% increase in insurance premiums in 2024. Among the many contributing factors are the increased utilization and cost of GLP-1 medications indicated for weight loss and diabetes. To help organizations navigate this new landscape, WeightWatchers for Business is building on its 30+ years of science-backed expertise in the employer-sponsored healthcare space with a complete cost management and utilization strategy that includes preventing progression and facilitating remission of weight-related conditions, as well as managing weight before, during, and after pharmacotherapy. WeightWatchers for Business utilizes evidence-based clinical pathways and step therapy with proprietary de-escalation protocols designed to drive clinically significant outcomes while controlling cost.

09:12 EDT Smith-Midland Corp to begin production on $6.8M precast panel project - Smith-Midland Corporation will begin production on a $6.8M architectural precast panel project for the Baltimore Harbor Tunnel for Maryland Transportation Authority.

09:08 EDT Bon Natural Life signs MoU for distributing Jiangwang spirits in China - Bon Natural Life announced the signing of a Memorandum of Understanding, MoU, with Guangdong Jiangwang International Holdings Limited. This MOU allows the parties to negotiate the terms and conditions of a definitive agreement for BON to distribute Jiangwang's Chinese White Spirits and other related health products in China Markets. "We are honored to work with Jiangwang with their long history and solid reputation in the spirit and related health products," stated by Mr. Hu Yongwei, CEO of BON. " This is our first entry into the spirit industry. I believe we can promote this business and achieve tremendous development based on our R&D strength in spirit-related health food. This MOU is the first step of the cooperation with Jiangwang, and we expect to finalize the definitive distribution agreement and achieve mutual development in the future."

09:06 EDT Hanryu Holdings, Nature Republic enter $2.58M service agreement - Hanryu Holdings announced that Hanryu and Nature Republic have entered into a service agreement, valued at $2.58 million, to promote mutual growth through promotion, planning, advertising, and sales activities. This agreement includes the use of one-of-a-kind characters such as Hanryu's unique character 'Deok Gom,' as well as Nature Republic X FNS products and events to further grow brand reach and drive revenue on Hanryu's leading media platform, FANTOO. The revenue of 2022 and June 2023 of Hanryu was $889,045 and $630,973, and Hanryu can expect at least $3.2 million as the revenue of 2023 including this service agreement. If so, the revenue of 2023 of the Company might be increased at least by 261% compared with its revenue of 2022.

09:01 EDT Nuvve Holding awarded $1.9M grant by CEC - Nuvve Holding has received a proposed award of $1,910,703 by the California Energy Commission under the CEC's Electric School Bus Bi-Directional Infrastructure funding opportunity. The grant will fund Nuvve's groundbreaking project, RESCHOOL: Resilient Energy Solutions for Schools, which is intended to showcase the transformative potential of electric school buses and bi-directional charging infrastructure to enhance the resilience of California's power grid. The initial project phase includes plans to produce a scalable model for other California school districts to implement their own zero-emission and bi-directional infrastructure.

08:59 EDT enVVeno Medical announces expedited development plan for enVVe valve - enVVeno Medical announced a plan to expedite the development of enVVe, its transcatheter based replacement venous valve. The new plan should shorten the enVVe development cycle by approximately 6 months. The next step in the development of enVVe will be a six month pre-clinical GLP study, which the Company expects to begin in early 2024 and which is an FDA prerequisite for the enVVe pivotal trial. The Company expects to be ready to seek an Investigational Device Exepmtion for the enVVe pivotal trial at the end of 2024. The enVVe is a non-surgical, replacement venous valve delivered via a minimally invasive procedure requiring no general anesthesia or overnight hospital stay. The valve is made from specially formulated biocompatible nickel and titanium alloy, which self-expands once deployed, and has a delivery profile of only 13 Fr when crimped. The enVVe valve is designed to accommodate the natural dilation and contraction of the vein and will be available in three sizes to ensure a proper fit across a broad range of vein sizes. Severe Chronic Venous Insufficiency is a debilitating disease that most often occurs when valves inside of the veins of the leg fail, causing blood to flow in the wrong direction (reflux) and increased pressure within the veins of the leg. Symptoms of severe CVI include leg swelling, pain, edema, and recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such a sleeping, bathing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. In addition to enVVe, the Company is also developing the VenoValve, a replacement venous valve that is implanted via an open surgical procedure. enVVeno recently announced completion of enrollment for the SAVVE U.S. pivotal trial for the VenoValve, with topline safety data expected in Q4 of this year, and topline efficacy data expected in Q2 of 2024. enVVeno expects to have sufficient data to be eligible to file a PMA seeking FDA approval for the VenoValve in Q3 of 2024.

08:36 EDT Imunon appoints Ott to its scientific advisory board - IMUNON announces the appointment of Patrick Ott, M.D., Ph.D. to the Company's scientific advisory board. Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.

08:35 EDT VCI Global proposes acquisition of resort properties in Bali, Phuket - VCI Global has entered into a letter of intent to acquire the leasing rights of Impiana Private Villas Cemagi, Bali and Impiana Private Villas Kata Noi, Phuket from Impiana Sdn Bhd, through its subsidiary, V Capital Real Estate Sdn Bhd. Impiana Private Villas Cemagi comprises 6 villas covering over 604 sq m, which accounts for only 8% of its total land area, providing opportunity for future expansion when required. Impiana Private Villas Kata Noi in turn has 11 villas covering 1,105 sq m, covering less than 40% of its land area. "The acquisitions of Impiana Cemagi and Impiana Kata Noi are strategic investments. The bright prospects basically guarantee good returns on our investment. To optimise the potential value of these two resort properties, we intend to redevelop Impiana Cemagi while Impiana Kata Noi will be refurbished through V Capital Real Estate. More importantly, this is in line with our plans to seek more opportunities in the hospitality segment within the Southeast Asia region, following our recent partnership with YY Group Holding Limited," said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

08:34 EDT Presidio announces closing of merger, commencement of trading of Conduit - Presidio Property Trust (SQFT) announced the successful merger with and commencement of trading of Conduit Pharmaceuticals (CDT) now trading on Nasdaq under the ticker symbol CDT for common stock on the Global Market and ticker symbol CDTTW for warrants on the Capital Market. In connection with the completion of the merger, Presidio's sponsored SPAC Murphy Canyon Acquisition Corp. changed its name to Conduit Pharmaceuticals Inc. As a result of this transaction, Presidio now owns a total of 4,015,250 shares of Conduit and warrants to purchase 709,000 shares of Conduit. "Presidio is proud to have been a part of this successful SPAC transaction, reflecting our confidence in the growth and future prospects of Conduit," said Jack Heilbron, CEO of Presidio Property Trust. "We firmly believe in the strategy and leadership of Conduit, and we are excited about the possibilities that this de-SPAC brings to Presidio's shareholders, which can now finally be recognized as an asset on Presidio's balance sheet."

08:32 EDT FOXO Technologies interim CEO Mark White issues letter to shareholders - FOXO Technologies provided a letter to shareholders from the company's newly appointed interim CEO, Mark White. "While this has been a turbulent period for the Company, I am honored to take the helm of FOXO Technologies. Before accepting this role, I undertook a comprehensive review of the technology and market potential for FOXO's proprietary epigenetic biomarker technology, including detailed discussions with key opinion leaders, insurance executives, and others within the field. I am highly encouraged by the immense potential of this platform. However, the board and I recognized the immediate need for a new direction to unlock shareholder value. Towards this end, we are laser-focused on driving value by adopting a new, more cost-effective, go-to-market strategy, including consumer-facing AI technologies. This strategy would include a FOXO subscription-based app, utilizing existing health and wellness analytic tools, as well as leveraging AI, machine learning and epigenetic data, to enhance health, wellness, and longevity. We also plan to white-label and provide API connectivity to other operators in the sector. Given my background in AI and technology, I truly believe FOXO has tremendous assets with the potential to transform healthcare by providing subscribers with new tools that have the potential to extend and improve their quality of life. As part of our overall strategy, we are also exploring a variety of potential strategic alternatives, which could include the acquisition of complementary AI technologies and/or strategic sales of assets to maximize value for shareholders. This could include the implementation of a powerful new AI platform that I have been personally involved in before joining the Company. At the same time, we have immediately undertaken a significant initiative to streamline costs within the organization and eliminate non-core expenses. While I recognize that many of our shareholders are frustrated with the slow progress of the Company under prior management, I can assure you that the new team is highly experienced in delivering various AI, software, and technology solutions... Overall, I am encouraged by the new direction for the business, and I look forward to working closely with our Chairman, Bret Barnes, a true pioneer in the field of bioinformatics, with immense knowledge and understanding of the industry. We are also committed to regularly communicating with shareholders to keep you informed of developments as they unfold. I truly appreciate the support of our shareholders and believe the best days for FOXO lie ahead."

08:17 EDT LatAm Logistic Properties announces leases for facilities in Peru, Costa Rica - LatAm Logistic Properties announced the signing of lease agreements in three of its new logistic facilities, including two properties in Peru and one in Costa Rica. Given the new leases, LLP's multi-country operating portfolio will have an occupancy rate of approximately 99.4%/ The new leases, which comprise a total gross leasable area of 417,365 square feet, and represent approximately 6.0% of the existing portfolio, include the following: LatAm Lima Sur Logistic Park, Lima, Peru. A major Peruvian importing, marketing and distribution company, which distributes its own brands as well as many global brands, has pre-leased 222,700 square feet, or 100%, of Building B500 for a 10-year term. The facility is expected to be completed in the first quarter of 2024. LatAm Lima Sur Logistic Park is a six-building complex located in the Lurin district, a growing urban hub of Peru. Including the new lease, the total project occupancy for the Lima Sur complex will be approximately 95%. LatAm Callao Logistic Park, Callao, Peru. One of the leading mass consumer branded products companies in the Andean Region, headquartered in Peru and operating across several Latin American countries, has pre-leased 102,000 square feet, or approximately 62%, of Building B100 in this 4-building complex for a 6-year term. Strategically located in a modern complex adjacent to Jorge Chavez Airport, Building B100 is expected to be completed in late 2023. Including the new lease, the total project occupancy for the LatAm Callao complex will be approximately 85%. LatAm Verbena Logistic Park, San Jose, Costa Rica. A Fortune 500, US-based branded consumer products company has pre-leased 92,665 square feet, or approximately 60%, of a new facility under development, for a 5-year term. The facility is expected to be completed in the first quarter of 2024. The facility is located in the LatAm Verbena Logistic Park complex, which comprises a total of 834,000 square feet. Including the new lease, the total project occupancy for the Verbena complex will be approximately 94%.

08:08 EDT Arcutis Biotherapeutics announces FDA approval of ZORYVE for children 6 to 11 - Arcutis Biotherapeutics announced the U.S. Food and Drug Administration has approved the supplemental new drug application, sNDA, to expand the indication of ZORYVE cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. "Young children with plaque psoriasis lack treatment options, which is why today's decision by the FDA represents a meaningful advancement for this pediatric population, their parents, and caregivers," said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. "ZORYVE has been shown to be safe, well tolerated, and effective; all critical factors for treating children with plaque psoriasis. We are excited to now be able to expand the availability of ZORYVE to children as young as 6 years old, offering them and their families an important new steroid-free treatment option to consider along with their healthcare providers."

08:04 EDT Mobiv Acquisition Corp announces extension of deadline to complete combination - Mobiv Acquisition announced that, on October 5, 2023, it notified the trustee of the Company's trust account that it was extending the time available to the Company to consummate an initial business combination from October 8, 2023 to November 8, 2023. The Extension is the sixth of up to nine one-month extensions permitted under the Company's governing documents. In connection with such Extension, Mobiv will deposit an aggregate of $100,000.00 into the Company's trust account on or before October 8, 2023, on behalf of the Company.

07:47 EDT Connexa Sports sees 'extremely strong' consumer demand for Pickleball Launcher - Connexa Sports Technologies announced that its flagship consumer brand, Slinger Bag, has seen an extremely strong consumer demand for its latest product innovation in Pickleball, which, at this current rate of sale will soon rival that of its tennis counterpart, which debuted in late summer 2020 and has seen cumulative sales in excess of $30M. The company said, "Successful in tennis as a result of its disruptive, transportable, versatile and affordable Slinger Bag Launcher, the company has now mirrored that success with its Pickleball Launcher. Pickleball is widely regarded as one of the fastest growing sports in the USA with over 36 million players, growing at an average of 159% over the last three years. The sport, mainly played in doubles, is highly social and easy to play. It is popular amongst both men and women, with the largest age bracket being between 18 to 35 years old."

07:34 EDT ParaZero, OVRL announce Australian authorization for drone flights - ParaZero Technologies and OVRL announced a first-ever Australian authorization for drones to operate over populated areas and near people, when using ParaZero safety systems, approved by the Civil Aviation Safety Agency. With the use of ParaZero's advanced parachute safety technology, ParaZero regional partner, OVRL, has landed a precedent-setting historic approval for complex operations. OVRL's tailored safety case and Specific Operations Risk Assessment application helped facilitate the landmark approval, now paving the way for all organizations throughout Australia to benefit from similar operational approvals.

07:16 EDT Akili CEO Eddie Martucci transitions to board chair, Matt Franklin to succeed - Akili announced that Eddie Martucci transitioned to the role of board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5. Martucci replaces former board chair, Chamath Palihapitiya, who has resigned from the board, effective October 4. The leadership transition follows the company's announcement in September that it plans to shift from a prescription to a non-prescription business model. As the company progresses into this next phase. Franklin joined Akili in June 2022 as its president and chief operating officer.

07:03 EDT Renalytix says U.S. Patent Office allow claims related to kidneyintelX.dkd test - Renalytix announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test. These claims were filed under US Patent Application No. 16/671.256 by the Joslin Diabetes Center and this patent is exclusively licensed to Renalytix. KidneyintelX.dkd received Food and Drug Administration de Novo marketing authorization on June 29, 2023. The newly allowed claims further strengthen the core intellectual property underpinning the KidneyIntelX technology by directly incorporating sTNFR1 and sTNFR2 into a set of consolidated claims directed towards identifying risk of early kidney function decline, thereby enabling therapeutic strategies for those at increased risk of progressive decline. The Company believes this development reflects the Renalytix strategy of innovation in biomarker research, development and translation in collaboration with the Joslin Diabetes Center and other leading research partners globally. When taken together with other key milestones, such as FDA De Novo marketing authorization, broad insurance coverage and published clinical utility and outcomes data, Renalytix believes this increases its competitive advantage.

06:51 EDT Standard Power chooses NuScale's approved SMR technology - Standard Power announced its plans to develop two small modular reactor-powered facilities that will together produce nearly 2GW of clean, carbon free energy and has chosen to work with technology provider NuScale Power, the only technology provider and producer of SMRs that has obtained U.S. regulatory approval, and ENTRA1 Energy, an independent global energy development and production company, to support Standard Power's two projects. The facilities will be located in Ohio and Pennsylvania. Standard Power aims to use the carbon-free energy to power nearby data centers. As the technology provider, NuScale will provide its approved NuScale SMR Technology for these projects, the only SMR technology that has received design approval from the United States Nuclear Regulatory Commission - a world-class regulator for nuclear safety.

06:32 EDT Bristol Myers, Paradigm collaborate to build clinical trial operating model - Paradigm announced a collaboration with Bristol Myers Squibb to build a new end-to-end clinical trial operating model across design, recruitment, and data collection. Starting with oncology and expanding to other therapeutic areas, Paradigm will enable Bristol Myers Squibb to enroll patients from providers across the Paradigm Network of health systems, all of whom serve diverse groups of patients and already use Paradigm software to reduce the burden of clinical trial recruitment and operations. The administrative burden of running a clinical trial contributes to lack of access and inequitable enrollment. For example, currently less than five percent of patients with cancer enroll in clinical trials as part of their care journey. As a result, new treatments can be slow to come to market and millions of individuals who might benefit from a clinical trial are not given the option to participate. To address this, Paradigm has chosen to build an entirely new clinical trial operating ecosystem. Together, the organizations will design trials whose protocol requirements meet the practical constraints of community health provider organizations. Paradigm first brought its clinical trial software platform to community health providers, who provide the majority of care for cancer patients and other severe conditions, and serve populations that mirror the overall demographics of the United States. Over the past year, Paradigm has successfully collaborated with dozens of these provider organizations to expand their clinical research programs and provide patients with clinical trials as a care option, all while reducing staff workload.

06:03 EDT ChipMOS reports September revenue $59.3M, Q3 revenue $173.1M - ChipMOS reported its unaudited consolidated revenue for the month of September and for the third quarter ended September 30. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$32.24 to $1.00 as of September 29. Revenue for the third quarter was $173.1M, representing an increase of 2.5% from the second quarter of 2023, and an increase of 6.2% from the third quarter of 2022. The company noted revenue growth in the third quarter of 2023, both year over year and quarter over quarter, reflects healthier channel inventory levels, and stable loading levels of DDIC high-end test platform. Revenue for the month of September 2023 was $59.3M, representing an increase of 4.3% from August, and an increase of 20.2% from September 2022.

05:52 EDT Pioneer Natural jumps 10% to $237.41 after WSJ report of Exxon deal nearing

05:08 EDT Pan American Silver suspends operating activities at La Colorada mine - Pan American Silver has temporarily suspended all operating activities at its La Colorada mine in Mexico due to security concerns at the mine site and the surrounding area. In the early hours of October 5, the operation experienced an armed robbery of two trailers of concentrate. There were no physical injuries to our personnel in connection with the incident. In response to the current security situation in the area and Pan American's priority to protect the safety and security of our personnel, Pan American has temporarily suspended operations, project work and exploration at La Colorada. The mine site is currently secure, and Pan American has activated care and maintenance activities while it works with state and federal authorities regarding this incident. The suspension will continue until Pan American determines it is appropriate to resume operations.

05:05 EDT Denison Mines invests $15M in F3 Uranium - Denison Mines announced that it has entered into a binding agreement with F3 Uranium to make a $15M strategic investment in F3 in the form of unsecured convertible debentures.